Xencor (NASDAQ: XNCR) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Xencor to similar businesses based on the strength of its risk, profitability, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares Xencor and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xencor -121.04% -13.79% -9.76%
Xencor Competitors -5,519.96% -454.20% -42.50%

Insider and Institutional Ownership

76.9% of Xencor shares are owned by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.1% of Xencor shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Xencor and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Xencor $31.94 million -$40.41 million -23.14
Xencor Competitors $260.16 million $66.28 million -6.62

Xencor’s rivals have higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Xencor and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor 0 2 3 0 2.60
Xencor Competitors 761 3027 11171 227 2.72

Xencor currently has a consensus target price of $28.00, indicating a potential upside of 39.10%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.52%. Given Xencor’s higher possible upside, equities analysts plainly believe Xencor is more favorable than its rivals.

Volatility and Risk

Xencor has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Xencor’s rivals have a beta of 6.66, indicating that their average share price is 566% more volatile than the S&P 500.

Summary

Xencor rivals beat Xencor on 7 of the 12 factors compared.

About Xencor

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.